CD4 and cancer: Crude 10-year risk of first cancer diagnosis was highest for patients with viral loads between 200 and 999 copies/mL after six months of therapy, though this was largely due to imbalances in race, year of ART initiation, ART regimen, CD4 count, and study site; after controlling for these factors and other baseline confounders, there was no association between HIV RNA six months after ART initiation and first cancer risk.